[go: up one dir, main page]

SE8904239L - Ett rekombinat, humant faktor-viii-derivat - Google Patents

Ett rekombinat, humant faktor-viii-derivat

Info

Publication number
SE8904239L
SE8904239L SE8904239A SE8904239A SE8904239L SE 8904239 L SE8904239 L SE 8904239L SE 8904239 A SE8904239 A SE 8904239A SE 8904239 A SE8904239 A SE 8904239A SE 8904239 L SE8904239 L SE 8904239L
Authority
SE
Sweden
Prior art keywords
factor viii
human factor
dna segment
recombinate
derivate
Prior art date
Application number
SE8904239A
Other languages
Unknown language ( )
English (en)
Other versions
SE465222C5 (sv
SE465222B (sv
SE8904239D0 (sv
Inventor
A B Almstedt
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8904239(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Priority to SE8904239A priority Critical patent/SE465222C5/sv
Publication of SE8904239D0 publication Critical patent/SE8904239D0/sv
Priority to NZ236276A priority patent/NZ236276A/xx
Priority to DE69032600T priority patent/DE69032600T3/de
Priority to SG9603152A priority patent/SG66753A1/en
Priority to AT91901327T priority patent/ATE170219T1/de
Priority to CA002071875A priority patent/CA2071875C/en
Priority to BR909007921A priority patent/BR9007921A/pt
Priority to JP3501715A priority patent/JP2644084B2/ja
Priority to DK91901327T priority patent/DK0506757T4/da
Priority to AT97103685T priority patent/ATE232213T1/de
Priority to ES91901327T priority patent/ES2119769T5/es
Priority to PCT/SE1990/000809 priority patent/WO1991009122A1/en
Priority to DK97103685T priority patent/DK0786474T3/da
Priority to DE1999175066 priority patent/DE19975066I2/de
Priority to AU70393/91A priority patent/AU645539B2/en
Priority to DE69034040T priority patent/DE69034040T2/de
Priority to ES97103685T priority patent/ES2189897T3/es
Priority to EP91901327A priority patent/EP0506757B2/en
Priority to EP02009162A priority patent/EP1293513A3/en
Priority to EP97103685A priority patent/EP0786474B1/en
Priority to PT96208A priority patent/PT96208B/pt
Priority to IE451090A priority patent/IE904510A1/en
Publication of SE8904239L publication Critical patent/SE8904239L/sv
Publication of SE465222B publication Critical patent/SE465222B/sv
Priority to NO922325A priority patent/NO309041B1/no
Priority to FI922745A priority patent/FI104260B/sv
Priority to HU95P/P00489P priority patent/HU211504A9/hu
Publication of SE465222C5 publication Critical patent/SE465222C5/sv
Priority to HK99104067A priority patent/HK1019449A1/xx
Priority to HK98109933A priority patent/HK1009290A1/xx
Priority to LU90457C priority patent/LU90457I2/fr
Priority to NL990035C priority patent/NL990035I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
SE8904239A 1989-12-15 1989-12-15 Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning SE465222C5 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE8904239A SE465222C5 (sv) 1989-12-15 1989-12-15 Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
NZ236276A NZ236276A (en) 1989-12-15 1990-11-29 Dna encoding factor viii: comprising two polypeptide chains, a 90 kda a chain polypeptide and an 80 kda c chain polypeptide
EP02009162A EP1293513A3 (en) 1989-12-15 1990-12-06 A recombinant human factor VIII derivative
EP97103685A EP0786474B1 (en) 1989-12-15 1990-12-06 A recombinant human factor VIII derivative
DE1999175066 DE19975066I2 (de) 1989-12-15 1990-12-06 Rekombinanter Abk¦mmling des menschlichen Faktors III.
EP91901327A EP0506757B2 (en) 1989-12-15 1990-12-06 A recombinant human factor viii derivative
AT91901327T ATE170219T1 (de) 1989-12-15 1990-12-06 Rekombinanter abkömmling des menschlichen faktors iii
CA002071875A CA2071875C (en) 1989-12-15 1990-12-06 Recombinant human factor viii derivative
BR909007921A BR9007921A (pt) 1989-12-15 1990-12-06 Sequencia de dna codificando para um derivado de fator viii humano,recombinante biologicamente ativo,vetor de expressao recombinante,cellula haspedeira de origem animal,processo para a fabricacao de um derivado e derivado de fator viii humano
JP3501715A JP2644084B2 (ja) 1989-12-15 1990-12-06 組換えヒト▲ｖｉｉｉ▼因子誘導体
DK91901327T DK0506757T4 (da) 1989-12-15 1990-12-06 Rekombinant human faktor VIII derivat
AT97103685T ATE232213T1 (de) 1989-12-15 1990-12-06 Rekombinanter abkömmling des menschlichen faktors viii
ES91901327T ES2119769T5 (es) 1989-12-15 1990-12-06 Derivado del factor viii humano recombinante.
PCT/SE1990/000809 WO1991009122A1 (en) 1989-12-15 1990-12-06 A recombinant human factor viii derivative
DK97103685T DK0786474T3 (da) 1989-12-15 1990-12-06 Rekombinant human faktor VIII derivat
DE69032600T DE69032600T3 (de) 1989-12-15 1990-12-06 Rekombinanter abkömmling des menschlichen faktors iii
AU70393/91A AU645539B2 (en) 1989-12-15 1990-12-06 A recombinant human factor VIII derivative
DE69034040T DE69034040T2 (de) 1989-12-15 1990-12-06 Rekombinanter Abkömmling des menschlichen Faktors VIII
ES97103685T ES2189897T3 (es) 1989-12-15 1990-12-06 Un derivado del factor viii recombinante humano.
SG9603152A SG66753A1 (en) 1989-12-15 1990-12-06 A recombinant human factor viii derivative
IE451090A IE904510A1 (en) 1989-12-15 1990-12-14 A recombinant human factor viii derivative
PT96208A PT96208B (pt) 1989-12-15 1990-12-14 Processo de obtencao de uma sequencia de adn codificando um derivado recombinante do factor viii humano, de um vector e de celula recombinante e de preparacao do referido derivado.
NO922325A NO309041B1 (no) 1989-12-15 1992-06-12 DNA-sekvens, rekombinant ekspresjonsvektor og vertscelle omfattende DNA-sekvensen, samt fremgangsmÕte for fremstilling av human faktor VIII-derivat
FI922745A FI104260B (sv) 1989-12-15 1992-06-12 DNA som kodar för ett biologiskt aktivt rekombinanthumanfaktor VIII-derivat, rekombinant expressionsvektor och värdcell innehållande denna DNA, samt ett förfarande för framställning av ett biologisktaktivt rekombinant humanfaktor VIII-derivat
HU95P/P00489P HU211504A9 (en) 1989-12-15 1995-06-28 Recombinant human factor viii derivatives
HK99104067A HK1019449A1 (en) 1989-12-15 1998-08-14 A recombinant human factor viii derivative
HK98109933A HK1009290A1 (en) 1989-12-15 1998-08-14 A recombinant human factor viii derivative
LU90457C LU90457I2 (fr) 1989-12-15 1999-10-12 Refacto
NL990035C NL990035I2 (nl) 1989-12-15 1999-10-12 Een recombinante afgeleide van humane factor VIII.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8904239A SE465222C5 (sv) 1989-12-15 1989-12-15 Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning

Publications (4)

Publication Number Publication Date
SE8904239D0 SE8904239D0 (sv) 1989-12-15
SE8904239L true SE8904239L (sv) 1991-06-16
SE465222B SE465222B (sv) 1991-08-12
SE465222C5 SE465222C5 (sv) 1998-02-10

Family

ID=20377785

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8904239A SE465222C5 (sv) 1989-12-15 1989-12-15 Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning

Country Status (21)

Country Link
EP (3) EP0786474B1 (sv)
JP (1) JP2644084B2 (sv)
AT (2) ATE170219T1 (sv)
AU (1) AU645539B2 (sv)
BR (1) BR9007921A (sv)
CA (1) CA2071875C (sv)
DE (3) DE69032600T3 (sv)
DK (2) DK0506757T4 (sv)
ES (2) ES2119769T5 (sv)
FI (1) FI104260B (sv)
HK (2) HK1019449A1 (sv)
HU (1) HU211504A9 (sv)
IE (1) IE904510A1 (sv)
LU (1) LU90457I2 (sv)
NL (1) NL990035I2 (sv)
NO (1) NO309041B1 (sv)
NZ (1) NZ236276A (sv)
PT (1) PT96208B (sv)
SE (1) SE465222C5 (sv)
SG (1) SG66753A1 (sv)
WO (1) WO1991009122A1 (sv)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
DE69329795T2 (de) * 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
SE9300509D0 (sv) * 1993-02-16 1993-02-16 Kabi Pharmacia Ab Peg treatment
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
AU6455896A (en) * 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP1318198B1 (en) * 1996-05-14 2006-03-22 Biovitrum Ab Process for producing a recombinant polypeptide involving the addition of an inhibitor of chymotrypsins to the cell culture medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
US6797505B2 (en) * 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
CA2634674A1 (en) 1999-02-22 2000-08-24 Baxter International Inc. Novel albumin-free factor viii formulations
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
EP1460131A3 (en) * 2000-03-22 2005-06-01 Octagene GmbH Production of recombinant blood clotting factors in human cell lines
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
ES2394085T3 (es) 2002-07-09 2013-01-17 Baxter International Inc. Medio exento de proteínas animales para el cultivo de células
PT1596887T (pt) 2003-02-26 2022-04-14 Nektar Therapeutics Conjugados polímero-porção fator viii
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
ES2648241T3 (es) 2003-09-30 2017-12-29 The Trustees Of The University Of Pennsylvania Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
BR122016022033B8 (pt) 2004-11-12 2021-05-25 Bayer Healthcare Llc conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica
EP2514757A3 (en) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
ES2525143T3 (es) 2005-04-07 2014-12-18 The Trustees Of The University Of Pennsylvania Cápsides de AAVrh.64 modificado, composiciones que las contienen y usos de las mismas
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
AU2007204044B2 (en) 2006-01-04 2012-09-27 Takeda Pharmaceutical Company Limited Oligopeptide-free cell culture media
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
JP2009532351A (ja) 2006-03-31 2009-09-10 バクスター・インターナショナル・インコーポレイテッド ペグ化第ｖｉｉｉ因子
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
US9441030B2 (en) 2007-02-23 2016-09-13 Sk Chemicals Co., Ltd. Process for producing and purifying factor VIII and its derivatives
KR20150064246A (ko) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
DK2235197T3 (en) 2007-12-27 2017-10-09 Baxalta GmbH Methods of cell culture
KR101582841B1 (ko) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
MX2011008094A (es) 2009-02-03 2012-02-13 Amunix Operating Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
DK2440239T3 (en) 2009-06-09 2017-10-16 Prolong Pharmaceuticals Llc HEMOGLOBIN FORMATIONS
AU2010277438B2 (en) 2009-07-27 2015-08-20 Baxalta GmbH Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
DK2459224T3 (en) 2009-07-27 2016-07-25 Baxalta GmbH Blodstørkningsproteinkonjugater
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
GB0915481D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
SG10201907152YA (en) 2009-12-06 2019-09-27 Bioverativ Therapeutics Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
CN102869779A (zh) 2010-03-29 2013-01-09 宾夕法尼亚大学托管会 药理学诱导的转基因消融系统
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
CN103180439A (zh) 2010-07-09 2013-06-26 比奥根艾迪克依蒙菲利亚公司 嵌合凝血因子
US9321827B2 (en) 2010-09-15 2016-04-26 Novo Nordisk A/S Factor VIII variants having a decreased cellular uptake
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
CN103502458B (zh) 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
TWI764092B (zh) 2011-07-08 2022-05-11 美商百歐維拉提夫治療公司 因子viii嵌合及雜交多肽，及其使用方法
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
WO2013098676A1 (en) 2011-12-30 2013-07-04 Grifols, S.A. Method for purifying factor viii
KR102212098B1 (ko) 2012-01-12 2021-02-03 바이오버라티브 테라퓨틱스 인크. 키메라 인자 viii 폴리펩티드들과 이의 용도
JP6234378B2 (ja) 2012-01-12 2017-11-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 第ｖｉｉｉ因子療法を受けている個体における第ｖｉｉｉ因子に対する免疫原性を低下させる方法
CA2864904C (en) 2012-02-15 2023-04-25 Amunix Operating Inc. Factor viii compositions and methods of making and using same
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc CHIMERIC COAGULATION FACTORS
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
NZ703366A (en) 2012-07-11 2018-03-23 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
RU2500818C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАР227, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 2H5 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ ФАКТОРА VIII
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
FI3889173T3 (fi) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
EP3666283B1 (en) 2013-03-15 2022-06-08 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
EA201592022A1 (ru) 2013-06-28 2016-05-31 Байоджен Ма Инк. Расщепляемый тромбином линкер, содержащий xten, и его применение
EP3043813B1 (en) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
WO2015023894A1 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Recombinant factor viii proteins
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
HUE057005T2 (hu) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Oszlopon történõ vírusinaktiváló eljárások
EA201690817A1 (ru) 2013-10-22 2016-08-31 Дбв Текнолоджиз Способ лечения гемофилии индукцией толерантности к факторам крови
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EP4332839A3 (en) 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP3080274B1 (en) 2013-12-09 2020-06-03 Sangamo Therapeutics, Inc. Methods and compositions for genome engineering
DK4176894T3 (da) 2014-01-10 2024-05-27 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2016012595A1 (en) * 2014-07-25 2016-01-28 Csl Behring Gmbh Improved factor viii preparations suitable for therapeutic use and processes to obtain these
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN108093639B (zh) 2015-04-16 2022-07-19 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
HRP20221089T1 (hr) 2016-02-01 2022-11-25 Bioverativ Therapeutics Inc. Optimizirani geni faktora viii
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
JP2020500874A (ja) 2016-12-02 2020-01-16 バイオベラティブ セラピューティクス インコーポレイテッド キメラ凝固因子を使用して血友病性関節症を処置する方法
US12168776B2 (en) 2017-08-09 2024-12-17 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
AU2018338608A1 (en) 2017-09-27 2020-04-09 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
AU2019215063A1 (en) 2018-02-01 2020-09-03 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
IL312315A (en) 2018-04-04 2024-06-01 Sigilon Therapeutics Inc Implantable particles and related methods
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
WO2019222682A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
CA3108799A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
US20220233650A1 (en) 2019-06-19 2022-07-28 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
CN116209430A (zh) 2020-08-07 2023-06-02 阿米库斯治疗学公司 囊泡靶向蛋白及其用途
TW202323274A (zh) 2021-08-23 2023-06-16 美商百歐維拉提夫治療公司 優化因子viii基因
TW202346327A (zh) 2021-09-30 2023-12-01 美商百歐維拉提夫治療公司 編碼具有降低免疫原性的因子ｖｉｉｉ多肽之核酸
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
JP2525022B2 (ja) * 1986-01-03 1996-08-14 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド ▲ＶＩＩＩ▼：ｃ因子型タンパク質の改良生産方法
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
JPH0637425B2 (ja) * 1986-11-11 1994-05-18 株式会社クラレ 高沸点（メタ）アクリル酸エステルの製造方法
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JP2586092B2 (ja) * 1988-04-06 1997-02-26 三菱瓦斯化学株式会社 多官能（メタ）アクリル酸エステルの製造法
ES2112255T3 (es) * 1989-11-17 1998-04-01 Novo Nordisk As Complejos proteicos que tienen actividad del factor viii:c y su produccion.

Also Published As

Publication number Publication date
EP1293513A3 (en) 2003-04-02
JP2644084B2 (ja) 1997-08-25
NO922325D0 (no) 1992-06-12
LU90457I2 (fr) 2001-04-13
IE904510A1 (en) 1991-07-17
SG66753A1 (en) 2001-12-19
BR9007921A (pt) 1992-11-10
AU645539B2 (en) 1994-01-20
DK0786474T3 (da) 2003-03-03
DE69032600D1 (de) 1998-10-01
SE465222C5 (sv) 1998-02-10
PT96208B (pt) 1998-05-29
NL990035I1 (nl) 1999-12-01
EP0506757B2 (en) 2005-10-26
ATE170219T1 (de) 1998-09-15
DE69032600T3 (de) 2006-07-20
HK1019449A1 (en) 2000-02-11
DK0506757T4 (da) 2006-02-20
NO309041B1 (no) 2000-12-04
CA2071875A1 (en) 1991-06-16
CA2071875C (en) 2006-08-08
EP0506757B1 (en) 1998-08-26
AU7039391A (en) 1991-07-18
ATE232213T1 (de) 2003-02-15
SE465222B (sv) 1991-08-12
DE69034040D1 (de) 2003-03-13
DE69032600T2 (de) 1999-01-07
FI104260B1 (sv) 1999-12-15
WO1991009122A1 (en) 1991-06-27
ES2189897T3 (es) 2003-07-16
NL990035I2 (nl) 2000-01-03
PT96208A (pt) 1991-09-30
DE69034040T2 (de) 2003-11-20
EP0506757A1 (en) 1992-10-07
NO922325L (no) 1992-08-11
DK0506757T3 (da) 1999-05-25
ES2119769T5 (es) 2006-04-16
FI922745A0 (fi) 1992-06-12
HU211504A9 (en) 1995-11-28
EP0786474B1 (en) 2003-02-05
DE19975066I2 (de) 2005-07-07
EP1293513A2 (en) 2003-03-19
NZ236276A (en) 1993-03-26
JPH05502161A (ja) 1993-04-22
FI104260B (sv) 1999-12-15
EP0786474A1 (en) 1997-07-30
HK1009290A1 (en) 1999-05-28
SE8904239D0 (sv) 1989-12-15
ES2119769T3 (es) 1998-10-16

Similar Documents

Publication Publication Date Title
SE8904239L (sv) Ett rekombinat, humant faktor-viii-derivat
SE9100799D0 (sv) Recombinant human factor viii derivatives
ATE238345T1 (de) Protegrine
ATE209215T1 (de) Protegrine
DE69434083D1 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
NO971621D0 (no) Keratinocyttvekstfaktoranaloger
ATE93852T1 (de) Redox-aminsaeuren und diese enthaltende peptide.
ATE86260T1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
BR9301436A (pt) Peptideo,processo para a sua preparacao,aplicacao desse peptideo e agente farmaceutico
EA200000709A1 (ru) Бета-липотропин и его применения

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8904239-4